Loading…
Exagen Inc. reported Q2 2026 financial results and raised its FY2026 sales guidance.
EXAGEN INC. announced on 2026-08-04 XGN reported financial results for Q2 2026 and raised FY2026 sales guidance.
FY2026 Sales Guidance: $72.000M-$75.000M. The announcement cited Q2 EPS: $(0.13), Q2 EPS Estimate: $(0.19), Q2 Sales: $19.941M, Q2 Sales Estimate: $17.817M, and FY2026 Sales Estimate: $71.560M. Related filings: {"document":"10-Q","description":"Quarterly report","url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/0001274737-26-000047-index.htm"}.
EXAGEN INC. has a free float of 13,807,348 shares and 24,159,839 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.